Catalyst

Slingshot members are tracking this event:

Phase 2 six month data of CAP-1002 ALLSTAR trial for Myocardial infarction (heart attack) due 1Q 2017

Source Link:
http://www.irdirect.net/pr/release/id/1602810

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CAPR Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details ALLSTAR is open for enrollment at approximately 24 centers in the United States. If the interim analysis plan is implemented, we expect the trial to be fully enrolled in the third quarter of 2016 and the Company expects to report six-month data in the first quarter of 2017.
http://www.irdirect....
Additional Relevant Details Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson & Johnson, has entered into an exclusive option to license CAP-1002, which can be exercised anytime until 60 days after the six-month ALLSTAR Phase II data is available.
http://www.irdirect....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 12, 2017
Occurred Source:
http://www.irdirect.net/prviewer/release/id/2492977
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Data, Cap-1002, Allstar Trial, Myocardial Infarction, Heart Attack, 1q 2017
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.